Physician profile
Bernardo Campos
NPI 1215050398
$2,067.96
in general payments reported to CMS, 2019-2025
12 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $51.49 · 2022: $162 · 2023: $556 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,039 · Food and Beverage: $556 · Consulting Fee: $57.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,038.83 |
| Food and Beverage | $555.57 |
| Consulting Fee | $57.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $1,096.23 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $286.92 | 2019-2022 | |
| Becton, Dickinson and Company | $158.41 | 2023 | Arista Ah Flexitip |
| Bolton Medical INC | $149.49 | 2023 | Treo Abdominal Stent-Graft System |
| Tela Bio, INC. | $106.77 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Johnson and Johnson International | $105.82 | 2023 | Dermabond Prineo, Dermabond, Stratafix |
| Medtronic, INC. | $60.65 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $37.45 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.81 | 2023 | Livtencity |
| Eisai INC. | $17.10 | 2019 | |
| Dentsply Sirona INC | $15.27 | 2023 | Astra Tech Implant System |
| Intercept Pharmaceuticals, INC. | $14.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernardo Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.